Effectiveness and Cost-Effectiveness of Triple Therapy with Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis from the Brazilian Public Health System Perspective
ConclusionsTelaprevir is more effective and cost-effective than boceprevir. Our model may be applied for other settings with a few adjustments in the input parameters. (Source: Value in Health Regional Issues)
Source: Value in Health Regional Issues - May 18, 2019 Category: International Medicine & Public Health Source Type: research
Ombitasvir/paritaprevir/ritonavir + dasabuvir +/- ribavirin in real world hepatitis C patients.
CONCLUSION: In an all-comers HCV GT1 population, 12 or 24-wk of OBV/PTV/r + DSV +/- RBV is highly effective and tolerable and results in better mental and physical health following treatment.
PMID: 31143073 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - May 13, 2019 Category: Gastroenterology Authors: Loo N, Lawitz E, Alkhouri N, Wells J, Landaverde C, Coste A, Salcido R, Scott M, Poordad F Tags: World J Gastroenterol Source Type: research
Prevalence of baseline NS3 resistance-associated substitutions (RASs) on treatment with protease inhibitors in patients infected with HCV genotype 1
ConclusionsOur results indicated that Brazilian isolates of HCV present a distinct pattern of RAS depending on the infecting viral subtype. In contrast to data from other countries, RAS Q80K prevalence in Brazil is low in HCV subtype 1a. This study improves the knowledge of genetic barrier for resistance to PIs involving RASs in chronically infected patients and its possible impact on an unsuccessful treatment outcome, information that might be crucial to upcoming decisions of incorporation of new DAAs in Brazilian guidelines of antiviral therapy against HCV infection. (Source: Clinics and Research in Hepatology and Gastroenterology)
Source: Clinics and Research in Hepatology and Gastroenterology - March 16, 2019 Category: Gastroenterology Source Type: research
High response and re ‐infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme
This article is protected by copyright. All rights reserved. (Source: Journal of Viral Hepatitis)
Source: Journal of Viral Hepatitis - November 13, 2018 Category: Infectious Diseases Authors: Jasmine Schulkind,
Brian Stephens,
Farsana Ahmad,
Linda Johnston,
Sharon Hutchinson,
Donna Thain,
Zoe Ward,
Peter Vickerman,
Matt Hickman,
John F Dillon Tags: Original Paper Source Type: research
HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape
Regimens based on direct-acting antivirals (DAAs) have revolutionized treatment of patients with chronic infection with hepatitis C virus (HCV), which globally has been estimated to cause 70-150 million chronic infections and at least 400.000 annual deaths[1,2]. Approved DAAs target the HCV protease (NS3P), NS5A and NS5B[3,4]. Protease inhibitors (PIs), available since 2011, constitute an important component of DAA-based combination therapies[3 –5]. While the initially developed PIs telaprevir and boceprevir have been discontinued, simeprevir might be used for treatment of patients infected with genotype 1, and grazoprev...
Source: Journal of Hepatology - November 2, 2018 Category: Gastroenterology Authors: Long V. Pham, Sanne Brun Jensen, Ulrik Fahn øe, Martin Schou Pedersen, Qi Tang, Lubna Ghanem, Santseharay Ramirez, Daryl Humes, Stéphanie B.N. Serre, Kristian Schønning, Jens Bukh, Judith M. Gottwein Source Type: research
Drug-Drug Interactions Potential of Direct Acting Antivirals for the treatment of Chronic Hepatitis C infection
Hepatitis C virus (HCV) infection is still a major global problem. Approximately, 71 million people were living with HCV worldwide in 2017 [1]. The primary objective of HCV treatment is to obtain a complete eradication of the virus, which is characterized as a sustained virological response (SVR). SVR is defined by an undetectable HCV RNA at 12 weeks after the end of treatment [2,3]. The management of HCV-infected patients has rapidly changed in the recent years. After the breakthrough of first-generation direct acting antiviral agents (DAAs), boceprevir and telaprevir, many DAAs targeting specific proteins of the HCV life...
Source: International Journal of Antimicrobial Agents - October 27, 2018 Category: Drugs & Pharmacology Authors: Nad ège Néant, Caroline Solas Tags: Themed Issue: Therapeutics of hepatitis viruses Source Type: research
Antiviral with HDAC inhibitor: A Combined Approach Targeting Hepatocellular Carcinoma by HCV
Background: In Patna city of Bihar region, India in HCV claims to be one of the rapid growing viral diseases during the last five year studies. Hepatocellular carcinoma is a viral disease that chronically infects human and other mammals worldwide. It leads to serious cirrhosis, hepatitis cancer, hepatitis failure and liver fibrosis in humans. Drugs targeted viral proteins of HCV lifecycle (NS3/4A protease, NS5B polymerase and NS5A protein). Resistance against the most promising protease inhibitors, telaprevir, boceprevir, and ITMN-191 has emerged in clinical trials. (Source: International Journal of Infectious Diseases)
Source: International Journal of Infectious Diseases - July 27, 2018 Category: Infectious Diseases Authors: G. Sahoo, P. Das, V. Rabidas, R. Topno, R. Kumar, K. Pandey Tags: UMP. 750 Source Type: research
Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir.
Abstract
In 2012, the first-generation protease inhibitors telaprevir (TVR) and boceprevir (BOC) were introduced in the Brazilian health system for treatment of chronic hepatitis C, after their approval by the National Committee for Health Technology Incorporation (CONITEC). However, these medicines were discontinued in 2015. The short period of use in therapy and their high cost require a discussion about the consequences for patients and for the health system of the early incorporation of new therapies. The article presents a qualitative analysis of the incorporation process of both medications in Brazil...
Source: Revista do Instituto de Medicina Tropical de Sao Paulo - July 5, 2018 Category: Tropical Medicine Authors: Gomes LO, Teixeira MR, Rosa JAD, Feltrin AA, Rodrigues JPV, Vecchi MD, Carneiro JMM, Noblat LACB, Chachá SGF, Martinelli ALC, Pereira LRL, Silveira MPT, Blatt CR, Farias MR Tags: Rev Inst Med Trop Sao Paulo Source Type: research
Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry
Viral hepatitis C has long been the most common indication for liver transplantation (LT) in Europe and in the US, with over 20% of all LT candidates on the waiting list having chronic hepatitis C virus infection (HCV). 1-2 Until recently, expected survival rates for HCV infected liver graft recipients was the lowest among all indications, due to severe and rapid HCV recurrence with IFN based therapies giving low cure rates.[1 –3] The approval of first generation direct-acting antiviral agents (DAAs), Telaprevir and Boceprevir, in 2011, marked the beginning of a new era. (Source: Journal of Hepatology)
Source: Journal of Hepatology - June 22, 2018 Category: Gastroenterology Authors: Luca Saverio Belli, Giovanni Perricone, Rene Adam, Paolo A Cortesi, Mario Strazzabosco, Rita Facchetti, Vincent Karam, Mauro Salizzoni, Rafael Lopez Andujar, Costantino Fondevila, Paolo De Simone, Cristina Morelli, Joan Fabregat-Prous, Didier Samuel, Kosh Source Type: research
First-wave protease inhibitors for hepatitis C genotype 1 treatment: a real-life experience in Brazilian patients
CONCLUSIONS: In conclusion, the SVR rates in our study were lower than those reported in pre-marketing studies but were comparable to real-life data. ADRs, particularly hematological ADRs, were more common compared to those in previous studies and resulted in a high rate of treatment discontinuity. (Source: Revista da Sociedade Brasileira de Medicina Tropical)
Source: Revista da Sociedade Brasileira de Medicina Tropical - May 14, 2018 Category: Tropical Medicine Source Type: research
Interactions between the antiviral drug telaprevir and human serum albumin: a combined study with spectroscopic methods and molecular modeling
This study investigated the interaction between... The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - New J. Chem. latest articles)
Source: RSC - New J. Chem. latest articles - April 27, 2018 Category: Chemistry Authors: Xinnuo Xiong Source Type: research
Teledermatologist expert skin advice: A unique model of care for managing skin disorders and adverse drug reactions in hepatitis C patients.
CONCLUSIONS: Teledermatologist expert skin advice was regarded by clinicians as a valuable patient care service. The platform is a novel modality that supports patients undergoing specialised treatments at risk of cutaneous adverse drug reaction.
PMID: 29572811 [PubMed - as supplied by publisher] (Source: The Australasian Journal of Dermatology)
Source: The Australasian Journal of Dermatology - March 23, 2018 Category: Dermatology Authors: Charlston S, Siller G Tags: Australas J Dermatol Source Type: research
[ASAP] Influence of Polymer and Drug Loading on the Release Profile and Membrane Transport of Telaprevir
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.8b00104 (Source: Molecular Pharmaceutics)
Source: Molecular Pharmaceutics - March 21, 2018 Category: Drugs & Pharmacology Authors: Laura I. Mosquera-Giraldo, Na Li, Venecia R. Wilson, Brittany L.B. Nichols, Kevin J. Edgar, Lynne S. Taylor Source Type: research
The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort.
CONCLUSION: PI triple regimes were highly effective in treatment-naïve patients without cirrhosis, but in this real-world cohort an inferior effect was evident in cirrhotic and treatment-experienced patients. Although tested on a limited sample, the baseline resistance testing seems to have no impact on prediction of therapy outcome. The reason could be that the baseline RASs T54S and V55A have relatively low resistance towards BOC and TVR. Emerging RASs, mainly R155K, with known high resistance to BOC and TVR were frequently found in non-responders.
PMID: 29536805 [PubMed - as supplied by publisher] (Source: Upsa...
Source: Upsala Journal of Medical Sciences - March 14, 2018 Category: General Medicine Authors: Kjellin M, Wesslén T, Löfblad E, Lennerstrand J, Lannergård A Tags: Ups J Med Sci Source Type: research
Results of interferon-based treatments in Alaska Native and American Indian population with chronic hepatitis C.
Conclusions We had success with pegylated interferon-based treatment of AN/AI people with genotypes 2 and 3. However, there were low SVR and high discontinuation rates for those with genotype 1.
PMID: 29516827 [PubMed] (Source: International Journal of Circumpolar Health)
Source: International Journal of Circumpolar Health - March 10, 2018 Category: International Medicine & Public Health Tags: Int J Circumpolar Health Source Type: research
